Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.

Liebig S, Stoeckmann N, Geier A, Rau M, Schattenberg JM, Bahr MJ, Manns MP, Jaeckel E, Schulze-Osthoff K, Bantel H.

Clin Transl Gastroenterol. 2019 Aug;10(8):e00066. doi: 10.14309/ctg.0000000000000066.

2.

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program.

Huber Y, Pfirrmann D, Gebhardt I, Labenz C, Gehrke N, Straub BK, Ruckes C, Bantel H, Belda E, Clément K, Leeming DJ, Karsdal MA, Galle PR, Simon P, Schattenberg JM.

Aliment Pharmacol Ther. 2019 Oct;50(8):930-939. doi: 10.1111/apt.15427. Epub 2019 Jul 25.

PMID:
31342533
3.

Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis.

Taubert R, Diestelhorst J, Junge N, Kirstein MM, Pischke S, Vogel A, Bantel H, Baumann U, Manns MP, Wedemeyer H, Jaeckel E.

Sci Rep. 2018 Nov 28;8(1):17452. doi: 10.1038/s41598-018-35882-7.

4.

Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study.

Geier A, Eichinger M, Stirnimann G, Semela D, Tay F, Seifert B, Tschopp O, Bantel H, Jahn D, Marques Maggio E, Saleh L, Bischoff-Ferrari HA, Müllhaupt B, Dufour JF.

Scand J Gastroenterol. 2018 Sep;53(9):1114-1120. doi: 10.1080/00365521.2018.1501091. Epub 2018 Sep 29.

PMID:
30270688
5.

Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.

Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan MY, Hampe J, Berg T, Trautwein C.

Gut. 2019 Jun;68(6):1099-1107. doi: 10.1136/gutjnl-2018-316228. Epub 2018 Aug 1.

PMID:
30068662
6.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H.

J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.

7.

Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection.

Wandrer F, Han B, Liebig S, Schlue J, Manns MP, Schulze-Osthoff K, Bantel H.

Aliment Pharmacol Ther. 2018 Aug;48(3):270-280. doi: 10.1111/apt.14802. Epub 2018 Jun 4.

PMID:
29863282
8.

Transjugular diagnostics in acute liver failure including measurements of hepatocentral venous biomarker gradients.

Wang MC, Wandrer F, Schlué J, Voigtländer T, Lankisch TO, Manns MP, Bantel H, von Hahn T.

Hepatol Res. 2018 Oct;48(11):914-925. doi: 10.1111/hepr.13185. Epub 2018 Jun 5.

PMID:
29726061
9.

Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers.

Krawczyk M, Bantel H, Rau M, Schattenberg JM, Grünhage F, Pathil A, Demir M, Kluwe J, Boettler T, Weber SN, Geier A, Lammert F; NAFLD Clinical Study Group (NAFLD CSG).

J Hum Genet. 2018 May;63(5):621-626. doi: 10.1038/s10038-018-0420-4. Epub 2018 Feb 26.

PMID:
29483677
10.

Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication.

Bantel H, Canbay A.

Gut. 2018 Jul;67(7):1206-1207. doi: 10.1136/gutjnl-2017-315630. Epub 2018 Jan 20. No abstract available.

PMID:
29353250
11.

Ethanol sensitizes hepatocytes for TGF-β-triggered apoptosis.

Gaitantzi H, Meyer C, Rakoczy P, Thomas M, Wahl K, Wandrer F, Bantel H, Alborzinia H, Wölfl S, Ehnert S, Nüssler A, Bergheim I, Ciuclan L, Ebert M, Breitkopf-Heinlein K, Dooley S.

Cell Death Dis. 2018 Jan 19;9(2):51. doi: 10.1038/s41419-017-0071-y.

12.

Macrophage p38 kinase inhibition for liver regeneration.

Schulze-Osthoff K, Bantel H.

FEBS J. 2017 Dec;284(24):4196-4199. doi: 10.1111/febs.14330.

13.

Increased apoptosis of regulatory T cells in patients with active autoimmune hepatitis.

John K, Hardtke-Wolenski M, Jaeckel E, Manns MP, Schulze-Osthoff K, Bantel H.

Cell Death Dis. 2017 Dec 14;8(12):3219. doi: 10.1038/s41419-017-0010-y. No abstract available.

14.

Hepatic Amiodarone Lipotoxicity Is Ameliorated by Genetic and Pharmacological Inhibition of Endoplasmatic Reticulum Stress.

Erez N, Hubel E, Avraham R, Cohen R, Fishman S, Bantel H, Manns M, Tirosh B, Zvibel I, Shibolet O.

Toxicol Sci. 2017 Oct 1;159(2):402-412. doi: 10.1093/toxsci/kfx143.

PMID:
28962527
15.

miR-223 represents a biomarker in acute and chronic liver injury.

Schueller F, Roy S, Loosen SH, Alder J, Koppe C, Schneider AT, Wandrer F, Bantel H, Vucur M, Mi QS, Trautwein C, Luedde T, Roderburg C.

Clin Sci (Lond). 2017 Jul 13;131(15):1971-1987. doi: 10.1042/CS20170218. Print 2017 Aug 1.

PMID:
28646120
16.

miR-1224 inhibits cell proliferation in acute liver failure by targeting the antiapoptotic gene Nfib.

Roy S, Bantel H, Wandrer F, Schneider AT, Gautheron J, Vucur M, Tacke F, Trautwein C, Luedde T, Roderburg C.

J Hepatol. 2017 Nov;67(5):966-978. doi: 10.1016/j.jhep.2017.06.007. Epub 2017 Jun 21.

PMID:
28645739
17.

Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis.

Taubert R, Hardtke-Wolenski M, Noyan F, Lalanne C, Jonigk D, Schlue J, Krech T, Lichtinghagen R, Falk CS, Schlaphoff V, Bantel H, Muratori L, Manns MP, Jaeckel E.

PLoS One. 2017 Jun 8;12(6):e0179074. doi: 10.1371/journal.pone.0179074. eCollection 2017.

18.

Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis.

Dengler M, Staufer K, Huber H, Stauber R, Bantel H, Weiss KH, Starlinger P, Pock H, Klöters-Plachky P, Gotthardt DN, Rauch P, Lackner C, Stift J, Brostjan C, Gruenberger T, Kumada T, Toyoda H, Tada T, Weiss TS, Trauner M, Mikulits W.

Oncotarget. 2017 Jul 11;8(28):46234-46248. doi: 10.18632/oncotarget.17598.

19.

The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.

Geier A, Macias RI, Bettinger D, Weiss J, Bantel H, Jahn D, Al-Abdulla R, Marin JJ.

Oncotarget. 2017 Feb 28;8(9):15846-15857. doi: 10.18632/oncotarget.15029.

20.

The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.

Krawczyk M, Rau M, Grünhage F, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Geier A, Lammert F; NAFLD Clinical Study Group (NAFLD CSG).

Hepatology. 2017 Aug;66(2):666-667. doi: 10.1002/hep.29100. Epub 2017 Jul 4. No abstract available.

PMID:
28176361
21.

Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.

Mueller S, Nahon P, Rausch V, Peccerella T, Silva I, Yagmur E, Straub BK, Lackner C, Seitz HK, Rufat P, Sutton A, Bantel H, Longerich T.

Hepatology. 2017 Jul;66(1):96-107. doi: 10.1002/hep.29099. Epub 2017 May 9.

PMID:
28170108
22.

Letter: cytokeratin-18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization. Authors' reply.

Bantel H, Wandrer F, Bock B, Kirstein MM, Schulze-Osthoff K.

Aliment Pharmacol Ther. 2017 Jan;45(1):184-185. doi: 10.1111/apt.13826. No abstract available.

23.

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.

Krawczyk M, Rau M, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Lammert F, Geier A; NAFLD Clinical Study Group.

J Lipid Res. 2017 Jan;58(1):247-255. doi: 10.1194/jlr.P067454. Epub 2016 Nov 11.

24.

Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation.

Bock B, Hasdemir D, Wandrer F, Rodt T, Manns MP, Schulze-Osthoff K, Bantel H.

Aliment Pharmacol Ther. 2016 Oct;44(7):747-54. doi: 10.1111/apt.13758. Epub 2016 Aug 3.

25.

Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients.

Attia D, Bantel H, Lenzen H, Manns MP, Gebel MJ, Potthoff A.

Aliment Pharmacol Ther. 2016 Aug;44(4):366-79. doi: 10.1111/apt.13710. Epub 2016 Jun 30.

26.

MicroRNA-125b-5p mimic inhibits acute liver failure.

Yang D, Yuan Q, Balakrishnan A, Bantel H, Klusmann JH, Manns MP, Ott M, Cantz T, Sharma AD.

Nat Commun. 2016 Jun 23;7:11916. doi: 10.1038/ncomms11916.

27.

Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury.

Roy S, Benz F, Alder J, Bantel H, Janssen J, Vucur M, Gautheron J, Schneider A, Schüller F, Loosen S, Luedde M, Koch A, Tacke F, Luedde T, Trautwein C, Roderburg C.

Clin Sci (Lond). 2016 Jul 1;130(14):1197-207. doi: 10.1042/CS20160216. Epub 2016 Apr 18.

PMID:
27129188
28.

Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver.

Ku NO, Strnad P, Bantel H, Omary MB.

Hepatology. 2016 Sep;64(3):966-76. doi: 10.1002/hep.28493. Epub 2016 Apr 4. Review.

29.

Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach.

Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H, John K, Boland KC, McNamara DA, Kay EW, Bantel H, Schulze-Bergkamen H, Prehn JH.

Cell Death Dis. 2016 Feb 4;7:e2087. doi: 10.1038/cddis.2016.7.

30.

Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver.

Rau M, Schilling AK, Meertens J, Hering I, Weiss J, Jurowich C, Kudlich T, Hermanns HM, Bantel H, Beyersdorf N, Geier A.

J Immunol. 2016 Jan 1;196(1):97-105. doi: 10.4049/jimmunol.1501175. Epub 2015 Nov 30.

31.

Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.

Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, Müllhaupt B, Geier A.

PLoS One. 2015 Nov 13;10(11):e0142661. doi: 10.1371/journal.pone.0142661. eCollection 2015.

32.

Interferon-Mediated Cytokine Induction Determines Sustained Virus Control in Chronic Hepatitis C Virus Infection.

Wandrer F, Falk CS, John K, Skawran B, Manns MP, Schulze-Osthoff K, Bantel H.

J Infect Dis. 2016 Mar 1;213(5):746-54. doi: 10.1093/infdis/jiv505. Epub 2015 Oct 26.

PMID:
26503984
33.

[S2k Guideline non-alcoholic fatty liver disease].

Roeb E, Steffen HM, Bantel H, Baumann U, Canbay A, Demir M, Drebber U, Geier A, Hampe J, Hellerbrand C, Pathil-Warth A, Schattenberg JM, Schramm C, Seitz HK, Stefan N, Tacke F, Tannapfel A, Lynen Jansen P, Bojunga J.

Z Gastroenterol. 2015 Jul;53(7):668-723. doi: 10.1055/s-0035-1553193. Epub 2015 Jul 13. German. No abstract available.

PMID:
26167698
34.

[First data concerning the medical supply of patients with non-alcoholic fatty liver disease in Germany - a survey in university hospital centers of hepatology].

Weiss J, Rau M, Bantel H, Bock H, Demir M, Kluwe J, Krawczyk M, Pathil-Warth A, Schattenberg JM, Tacke F, Roeb E, Geier A; Klinische Studiengruppe NAFLD (NAFLD CSG):.

Z Gastroenterol. 2015 Jun;53(6):562-7. doi: 10.1055/s-0034-1399180. Epub 2015 Jun 15. German.

PMID:
26079073
35.

Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients.

John K, Rösner I, Keilholz U, Gauler T, Bantel H, Grünwald V.

Eur J Cancer. 2015 Aug;51(12):1596-602. doi: 10.1016/j.ejca.2015.05.021. Epub 2015 Jun 2.

PMID:
26048456
36.

Reply: To PMID 24913549.

Bantel H, Thum T, Schulze-Osthoff K.

Hepatology. 2015 Apr;61(4):1440-1. doi: 10.1002/hep.27352. Epub 2015 Mar 9. No abstract available.

PMID:
25130309
37.

MicroRNAs play a role in spontaneous recovery from acute liver failure.

John K, Hadem J, Krech T, Wahl K, Manns MP, Dooley S, Batkai S, Thum T, Schulze-Osthoff K, Bantel H.

Hepatology. 2014 Oct;60(4):1346-55. doi: 10.1002/hep.27250. Epub 2014 Aug 25.

PMID:
24913549
38.

[Cytokeratin 18 as marker for non-invasive diagnosis and prognosis of acute and chronic liver diseases].

Canbay A, Feldstein A, Kronenberger B, Schulze-Osthoff K, Bantel H.

Z Gastroenterol. 2014 Mar;52(3):290-5. doi: 10.1055/s-0033-1356138. Epub 2014 Mar 12. Review. German.

PMID:
24622872
39.

BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.

Breunig C, Mueller BJ, Umansky L, Wahl K, Hoffmann K, Lehner F, Manns MP, Bantel H, Falk CS.

Clin Cancer Res. 2014 May 1;20(9):2410-23. doi: 10.1158/1078-0432.CCR-13-1635. Epub 2014 Feb 26.

40.

Increased HEV seroprevalence in patients with autoimmune hepatitis.

Pischke S, Gisa A, Suneetha PV, Wiegand SB, Taubert R, Schlue J, Wursthorn K, Bantel H, Raupach R, Bremer B, Zacher BJ, Schmidt RE, Manns MP, Rifai K, Witte T, Wedemeyer H.

PLoS One. 2014 Jan 21;9(1):e85330. doi: 10.1371/journal.pone.0085330. eCollection 2014.

41.

Robust detection of liver steatosis and staging of NAFLD by an improved ELISA for serum cytokeratin-18 fragments.

Bantel H, John K, Schulze-Osthoff K.

Am J Gastroenterol. 2014 Jan;109(1):140-1. doi: 10.1038/ajg.2013.350. No abstract available.

PMID:
24402545
42.

Increased plasma levels of CK-18 as potential cell death biomarker in patients with HELLP syndrome.

John K, Wielgosz S, Schulze-Osthoff K, Bantel H, Hass R.

Cell Death Dis. 2013 Oct 24;4:e886. doi: 10.1038/cddis.2013.408.

43.

Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage disease.

Puls F, Goldschmidt I, Bantel H, Agne C, Bröcker V, Dämmrich M, Lehmann U, Berrang J, Pfister ED, Kreipe HH, Baumann U.

J Hepatol. 2013 Sep;59(3):626-30. doi: 10.1016/j.jhep.2013.05.018. Epub 2013 May 23.

44.

The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.

Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ.

J Hepatol. 2013 Aug;59(2):236-42. doi: 10.1016/j.jhep.2013.03.016. Epub 2013 Mar 21. Erratum in: J Hepatol. 2013 Dec;59(6):1365.

PMID:
23523583
45.

Increased epithelial permeability is the primary cause for bicarbonate loss in inflamed murine colon.

Juric M, Xiao F, Amasheh S, May O, Wahl K, Bantel H, Manns MP, Seidler U, Bachmann O.

Inflamm Bowel Dis. 2013 Apr;19(5):904-11. doi: 10.1097/MIB.0b013e3182813322.

PMID:
23502355
46.

Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.

Wahl K, Rosenberg W, Vaske B, Manns MP, Schulze-Osthoff K, Bahr MJ, Bantel H.

PLoS One. 2012;7(12):e51906. doi: 10.1371/journal.pone.0051906. Epub 2012 Dec 19.

47.

Selective protection of human liver tissue in TNF-targeting of cancers of the liver by transient depletion of adenosine triphosphate.

Weiland T, Klein K, Zimmermann M, Speicher T, Venturelli S, Berger A, Bantel H, Königsrainer A, Schenk M, Weiss TS, Wendel A, Schwab M, Bitzer M, Lauer UM.

PLoS One. 2012;7(12):e52496. doi: 10.1371/journal.pone.0052496. Epub 2012 Dec 18.

48.

Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.

Wahl K, Siegemund M, Lehner F, Vondran F, Nüssler A, Länger F, Krech T, Kontermann R, Manns MP, Schulze-Osthoff K, Pfizenmaier K, Bantel H.

Hepatology. 2013 Feb;57(2):625-36. doi: 10.1002/hep.26082. Epub 2013 Jan 8.

PMID:
22991197
49.

Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).

Seidel C, Fenner M, Länger F, Bantel H, Ganser A, Grünwald V.

BMC Cancer. 2012 May 21;12:186. doi: 10.1186/1471-2407-12-186.

50.

TNF Antagonists in IBD: Novel Antiinflammatory Mechanisms Beyond Cytokine Inhibition.

Bantel H, Schulze-Osthoff K.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):E51-2. doi: 10.1002/ibd.22988. No abstract available.

PMID:
22535584

Supplemental Content

Loading ...
Support Center